Cellectis Gestione

Gestione criteri di controllo 3/4

Cellectis Il CEO è Andre Choulika, nominato in Jan1999, e ha un mandato di 25.83 anni. la retribuzione annua totale è $ 876.60K, composta da 99.8% di stipendio e 0.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.02% delle azioni della società, per un valore di € 1.76M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 7.7 anni.

Informazioni chiave

Andre Choulika

Amministratore delegato

US$876.6k

Compenso totale

Percentuale dello stipendio del CEO	99.8%
Mandato del CEO	25.8yrs
Proprietà del CEO	1.0%
Durata media del management	4.3yrs
Durata media del Consiglio di amministrazione	7.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Andre Choulika rispetto agli utili di Cellectis?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$84m
Jun 30 2024	n/a	n/a	-US$79m
Mar 31 2024	n/a	n/a	-US$78m
Dec 31 2023	US$877k	US$875k	-US$109m
Sep 30 2023	n/a	n/a	-US$92m
Jun 30 2023	n/a	n/a	-US$97m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$744k	US$744k	-US$91m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$99m
Dec 31 2021	US$879k	US$879k	-US$86m
Sep 30 2021	n/a	n/a	-US$129m
Jun 30 2021	n/a	n/a	-US$121m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$1m	US$1m	-US$37m
Sep 30 2020	n/a	n/a	-US$79m
Jun 30 2020	n/a	n/a	-US$66m
Mar 31 2020	n/a	n/a	-US$67m
Dec 31 2019	US$1m	US$1m	-US$102m

Compensazione vs Mercato: La retribuzione totale di Andre ($USD 876.60K ) è circa la media per le aziende di dimensioni simili nel mercato UK ($USD 736.76K ).

Compensazione vs guadagni: La retribuzione di Andre è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Andre Choulika (59 yo)

25.8yrs

Mandato

US$876,597

Compensazione

Dr. Andre Choulika, Ph.D. is the Founder of Cellectis S.A. and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. He is the Director of Cellectis...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Andre Choulika	Co-Founder	25.8yrs	US$876.60k	1.02% € 1.8m
David j. Sourdive	Deputy CEO	no data	US$557.84k	0.31% € 529.2k
Arthur Stril	Interim Chief Financial Officer	less than a year	Nessun dato	0.0086% € 14.8k
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	2.9yrs	Nessun dato	Nessun dato
Jean Epinat	Chief Technological Officer	no data	Nessun dato	Nessun dato
Philippe Duchateau	Chief Scientific Officer	12.8yrs	Nessun dato	0.043% € 74.7k
Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	11.8yrs	Nessun dato	0.031% € 52.8k
Pascalyne Wilson	Director of Communications	no data	Nessun dato	Nessun dato
Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer	4yrs	Nessun dato	0.012% € 20.1k
Stephan Reynier	Chief Regulatory & Pharmaceutical Compliance Officer	no data	Nessun dato	0.020% € 34.1k
Steven Doares	Senior VP of US Manufacturing & Site Head of the Raleigh	4.3yrs	Nessun dato	0.012% € 21.6k
Laurent Poirot	Senior Vice President of Immunology	no data	Nessun dato	Nessun dato

4.3yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di 0WA2 è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Andre Choulika	Co-Founder	25.8yrs	US$876.60k	1.02% € 1.8m
David j. Sourdive	Deputy CEO	24.8yrs	US$557.84k	0.31% € 529.2k
Jean-Pierre Garnier	Independent Non-Executive Chairman	4yrs	US$97.34k	0% € 0
Laurent Arthaud	Director	13.1yrs	Nessun dato	Nessun dato
Pierre Bastid	Independent Director	13.1yrs	US$97.34k	0.056% € 96.5k
Rainer Boehm	Independent Director	7.4yrs	US$99.60k	0% € 0
Dietger Niederwieser	Member of Clinical Advisory Board	7.7yrs	Nessun dato	Nessun dato
Kanti Rai	Member of Clinical Advisory Board	7.8yrs	Nessun dato	Nessun dato
Catherine Bollard	Member of Clinical Advisory Board	7.7yrs	Nessun dato	Nessun dato
Ola Landgren	Member of Clinical Advisory Board	7.7yrs	Nessun dato	Nessun dato
Marcela Maus	Member of Clinical Advisory Board	7.7yrs	Nessun dato	Nessun dato
Stephan Grupp	Member of Clinical Advisory Board	6.2yrs	Nessun dato	Nessun dato

7.7yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0WA2 sono considerati esperti (durata media dell'incarico 7.7 anni).

Cellectis Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Cellectis Announces Chief Financial Officer Changes

Cellectis S.A. Announces Board Appointments

Less than half of directors are independent

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Insufficient new directors

Recent updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 3Q 2023)

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

New major risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.28 loss per share (vs US$0.089 loss in 2Q 2023)

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

New minor risk - Profitability

First quarter 2024 earnings released: EPS: US$0.079 (vs US$0.49 loss in 1Q 2023)

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

New major risk - Shareholder dilution

New minor risk - Share price stability

Cellectis Announces Chief Financial Officer Changes

No longer forecast to breakeven

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.99 loss in FY 2022)

No longer forecast to breakeven

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.089 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

No longer forecast to breakeven

Now 21% undervalued after recent price drop

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.28 loss in 1Q 2021)

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Senior Vice President of Technical Operations - Europe Leopold Bertea has left the company

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.71 loss in 3Q 2020)